
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogents lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase...
Gastrointestinal stromal tumors (gist),oncology,systemic mastocytosis,and kinase inhibitors
Cogent biosciences operates in the Biotechnology research industry.
Cogent biosciences's revenue is 11m - 100m
Cogent biosciences has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.